當前位置：首頁 SCI期刊 SCIE期刊醫學中科院3區 JCRQ2 期刊介紹(非官網)

Advances In TherapySCIE

國際簡稱：ADV THER 參考譯名：治療進展

中科院分區
3區
CiteScore分區
Q1
JCR分區
Q2

基本信息：: ISSN：0741-238X; E-ISSN：1865-8652; 是否OA：未開放; 是否預警：否; TOP期刊：否

出版信息：: 出版地區：ENGLAND; 出版商：Springer Healthcare; 出版語言：English; 出版周期：Monthly; 出版年份：2000; 研究方向：醫學-藥學

評價信息：: 影響因子：3.4; H-index：53; CiteScore指數：7.2; SJR指數：1.089; SNIP指數：1.316

發文數據：: Gold OA文章占比：68.88%; 研究類文章占比：77.10%; 年發文量：345; 自引率：0.0263...; 開源占比：0.6908; 出版撤稿占比：0; 出版國人文章占比：0.07; OA被引用占比：0.7717...

投稿咨詢加急見刊

英文簡介期刊介紹 CiteScore數據中科院SCI分區 JCR分區發文數據常見問題

英文簡介Advances In Therapy期刊介紹

Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.

The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.

期刊簡介Advances In Therapy期刊介紹

《Advances In Therapy》自2000出版以來，是一本醫學優秀雜志。致力于發表原創科學研究結果，并為醫學各個領域的原創研究提供一個展示平臺，以促進醫學領域的的進步。該刊鼓勵先進的、清晰的闡述，從廣泛的視角提供當前感興趣的研究主題的新見解，或審查多年來某個重要領域的所有重要發展。該期刊特色在于及時報道醫學領域的最新進展和新發現新突破等。該刊近一年未被列入預警期刊名單，目前已被權威數據庫SCIE收錄，得到了廣泛的認可。

該期刊投稿重要關注點：

預計審稿時間：較慢,6-12周
醫學
MEDICINE, RESEARCH & EXPERIMENTAL
SCIE
中科院3區
非預警

Cite Score數據（2024年最新版）Advances In Therapy Cite Score數據

CiteScore：7.2
SJR：1.089
SNIP：1.316

學科類別	分區	排名	百分位
大類：Medicine 小類：Pharmacology (medical)	Q1	52 / 272	81%

CiteScore 是由Elsevier(愛思唯爾)推出的另一種評價期刊影響力的文獻計量指標。反映出一家期刊近期發表論文的年篇均引用次數。CiteScore以Scopus數據庫中收集的引文為基礎，針對的是前四年發表的論文的引文。CiteScore的意義在于，它可以為學術界提供一種新的、更全面、更客觀地評價期刊影響力的方法，而不僅僅是通過影響因子(IF)這一單一指標來評價。

歷年Cite Score趨勢圖

中科院SCI分區Advances In Therapy 中科院分區

中科院 2023年12月升級版 綜述期刊：否 Top期刊：否

大類學科	分區	小類學科	分區
醫學	3區	MEDICINE, RESEARCH & EXPERIMENTAL 醫學：研究與實驗 PHARMACOLOGY & PHARMACY 藥學	3區 3區

中科院分區表 是以客觀數據為基礎，運用科學計量學方法對國際、國內學術期刊依據影響力進行等級劃分的期刊評價標準。它為我國科研、教育機構的管理人員、科研工作者提供了一份評價國際學術期刊影響力的參考數據，得到了全國各地高校、科研機構的廣泛認可。

中科院分區表 將所有期刊按照一定指標劃分為1區、2區、3區、4區四個層次，類似于“優、良、及格”等。最開始，這個分區只是為了方便圖書管理及圖書情報領域的研究和期刊評估。之后中科院分區逐步發展成為了一種評價學術期刊質量的重要工具。

歷年中科院分區趨勢圖

JCR分區Advances In Therapy JCR分區

2023-2024 年最新版

按JIF指標學科分區	收錄子集	分區	排名	百分位
學科：MEDICINE, RESEARCH & EXPERIMENTAL	SCIE	Q2	76 / 189	60.1%
學科：PHARMACOLOGY & PHARMACY	SCIE	Q2	105 / 354	70.5%

按JCI指標學科分區	收錄子集	分區	排名	百分位
學科：MEDICINE, RESEARCH & EXPERIMENTAL	SCIE	Q2	71 / 189	62.7%
學科：PHARMACOLOGY & PHARMACY	SCIE	Q2	130 / 354	63.42%

JCR分區的優勢在于它可以幫助讀者對學術文獻質量進行評估。不同學科的文章引用量可能存在較大的差異，此時單獨依靠影響因子(IF)評價期刊的質量可能是存在一定問題的。因此，JCR將期刊按照學科門類和影響因子分為不同的分區，這樣讀者可以根據自己的研究領域和需求選擇合適的期刊。

歷年影響因子趨勢圖

發文數據

2023-2024 年國家/地區發文量統計

國家/地區數量
USA383
England161
CHINA MAINLAND131
Italy131
GERMANY (FED REP GER)108
Spain81
Switzerland72
Japan62
Canada61
France59

本刊中國學者近年發表論文

1、The Importance of Integrated Regulation Mechanism of Coronary Microvascular Function for Maintaining the Stability of Coronary Microcirculation: An Easily Overlooked Perspective
Author: Zhu, Houyong; Wang, Hanxin; Zhu, Xinyu; Chen, Qilan; Fang, Xiaojiang; Xu, Xiaoqun; Ping, Yan; Gao, Beibei; Tong, Guoxin; Ding, Yu; Chen, Tielong; Huang, Jinyu

Journal: ADVANCES IN THERAPY. 2023; Vol. 40, Issue 1, pp. 76-101. DOI: 10.1007/s12325-022-02343-7
2、Peripheral T-reg Levels and Transforming Growth Factor-beta (TGF beta) in Patients with Psoriatic Arthritis: A Systematic Review Meta-Analysis
Author: Su, Qin-Yi; Zhang, Sheng-Xiao; Yang, Liu; Luo, Jing; Li, Xiao-Feng; Zhang, Jia-Qi; Zhang, Yan; Liu, Jun-Qi; Shi, Lei

Journal: ADVANCES IN THERAPY. 2023; Vol. 40, Issue 1, pp. 102-116. DOI: 10.1007/s12325-022-02337-5
3、Identification and Validation of a Novel Glycolysis-Related Gene Signature for Predicting the Prognosis and Therapeutic Response in Triple-Negative Breast Cancer
Author: Zheng, Jian; Zhang, Yi-Fan; Han, Guo-Hui; Fan, Meng-Ying; Du, Ming-Hui; Zhang, Guo-Chen; Zhang, Bo; Qiao, Jun; Zhang, Sheng-Xiao; Cao, Ji-Min

Journal: ADVANCES IN THERAPY. 2023; Vol. 40, Issue 1, pp. 310-330. DOI: 10.1007/s12325-022-02330-y
4、Recurrence Rates and Pharmacological Treatment for Hemorrhoidal Disease: A Systematic Review
Author: Lohsiriwat, Varut; Sheikh, Parvez; Bandolon, Robert; Ren, Dong-Lin; Roslani, April Camilla; Schaible, Kassandra; Freitag, Andreas; Martin, Monique; Yaltirik, Pelin; Godeberge, Philippe

Journal: ADVANCES IN THERAPY. 2023; Vol. 40, Issue 1, pp. 117-132. DOI: 10.1007/s12325-022-02351-7
5、Cost-Effectiveness of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease from Chinese Healthcare Perspective
Author: Xie, Wenwen; Song, Yinyin; Qin, Xiaomei; Jin, Pengfei

Journal: ADVANCES IN THERAPY. 2023; Vol. 40, Issue 2, pp. 489-503. DOI: 10.1007/s12325-022-02372-2
6、Quick and Accurate Placement of Cannulated Screws to Internal Fixation of Femoral Neck Fractures Using a Novel Guide Device
Author: Ren, Bu-fang; Li, Gang; Ma, Quan-ping; Lv, Xin; Sun, Jian

Journal: ADVANCES IN THERAPY. 2023; Vol. 40, Issue 3, pp. 844-852. DOI: 10.1007/s12325-022-02374-0
7、Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis
Author: Liu, Yuwei; Pan, Jiahui; Gao, Fangbo; Xu, Wentao; Li, Hongyu; Qi, Xingshun

Journal: ADVANCES IN THERAPY. 2023; Vol. 40, Issue 2, pp. 521-549. DOI: 10.1007/s12325-022-02371-3
8、The MODIFY Study Protocol: An Open-Label, Single-Arm, Multicenter, Prospective Pragmatic Study of Ixazomib-Based Triple-Drug Therapy in Chinese Patients with Multiple Myeloma
Author: Chen, Wenming; Liu, Aijun; Li, Lin

Journal: ADVANCES IN THERAPY. 2023; Vol. 40, Issue 2, pp. 705-717. DOI: 10.1007/s12325-022-02355-3